Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2024; 15(3): 488-501
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.488
MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4
Qi-Shun Wu, Dan-Na Zheng, Cheng Ji, Hui Qian, Juan Jin, Qiang He
Qi-Shun Wu, Dan-Na Zheng, Qiang He, Graduate School, Medical College of Soochow University, Suzhou 215006, Jiangsu Province, China
Qi-Shun Wu, Dan-Na Zheng, Qiang He, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou 314408, Zhejiang Province, China
Qi-Shun Wu, Department of Nephrology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, Jiangsu Province, China
Dan-Na Zheng, Department of Nephrology, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou 314408, Zhejiang Province, China
Cheng Ji, Hui Qian, Molecular Inspection Laboratory, School of Medicine, Jiangsu University, Zhenjiang 212000, Jiangsu Province, China
Juan Jin, Qiang He, Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou 310060, Zhejiang Province, China
Author contributions: Wu QS conceived and designed the experiments. Wu QS and Zheng DN performed the experiments, analysed the data, and prepared all the figures; Ji C, Qian H, Jin J, and He Q provided technical support; Wu QS wrote the manuscript; and all authors contributed to the article and approved the submitted version.
Supported by the Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China, No. LHDMZ22H050001; the Construction of Key Projects by Zhejiang Provincial Ministry, No. WKJ-ZJ-2302; the Zhejiang Province Chinese Medicine Modernization Program, No. 2020ZX001; the Key Project of Scientific Research Foundation of Chinese Medicine, No. 2022ZZ002; the “Pioneer” and “LeadingGoose” R&D Program of Zhejiang, No. 2022C03118 and 2023C03075; and the Key Project of Basic Scientific Research Operating Funds of Hangzhou Medical College, No. KYZD202002.
Institutional review board statement: This study did not involve human experimentation.
Institutional animal care and use committee statement: The study was reviewed and approved by the Ethics Committee of the Laboratory Animal of Jiangsu University Institutional Review Board (Approval No. UJS-IACUC-AP-2022081615).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiang He, MD, Chief Physician, Professor, Graduate School, Medical College of Soochow University, No. 1 Shizi Street, Gusu District, Suzhou 215006, Jiangsu Province, China. strong_he@163.com
Received: August 31, 2023
Peer-review started: August 31, 2023
First decision: December 25, 2023
Revised: January 6, 2024
Accepted: January 29, 2024
Article in press: January 29, 2024
Published online: March 15, 2024
Processing time: 197 Days and 5.3 Hours
ARTICLE HIGHLIGHTS
Research background

Diabetic kidney disease (DKD) is a major complication of diabetes mellitus. Numerous studies have demonstrated that tubular epithelial cell (TEC) damage, which is strongly associated with the inflammatory response and mesenchymal trans-differentiation, plays a significant role in DKD; however, the precise molecular mechanism is unknown. The recently identified microRNA-630 (miR-630) has been hypothesized to be closely associated with cell migration, apoptosis, and autophagy.

Research motivation

The relationship between miR-630 and DKD and the underlying mechanism remains unknown.

Research objectives

The object of this study is to investigate how miR-630 affects TEC injury and the inflammatory response in DKD rats.

Research methods

Streptozotocin was administered to six-week-old male rats to create a hyperglycemic diabetic model, and in the second week of modeling, the rats were divided into control, DKD, negative control lentivirus, and miR-630 overexpression groups. After eight weeks, urine and blood samples were collected for the kidney injury assay, and renal tissues were removed for further molecular assays, such as real-time polymerase chain reaction, western blotting, enzyme-linked immunosorbent assay, and immunohistochemistry. The target gene for miR-630 was predicted using bioinformatics, and in vitro investigations and double luciferase reporter gene assays confirmed the association between miR-630 and toll-like receptor 4 (TLR4).

Research results

The expression level of miR-630 was decreased in the kidney tissue of rats with DKD (P < 0.05). In vitro experiments, the mRNA expression level of miR-630 was significantly lower in the high glucose (HG) and HG + mimic negative control (NC) groups than in the normal glucose group (P < 0.05). In contrast, the mRNA expression level of TLR4 was significantly higher in these groups (P < 0.05). The HG and HG + mimic NC groups showed a significant decrease in E-cadherin protein expression, whereas TLR4, α-smooth muscle actin (SMA), and collagen IV protein expression increased (P < 0.05). Conversely, compared with the HG + mimic NC group, a significant increase in E-cadherin protein expression and a notable decrease in TLR4, α-SMA, and collagen IV protein expression were observed in the HG + miR-630 mimic group (P < 0.05). In vivo experiments, DKD rats treated with miR-630 agomir exhibited significantly higher miR-630 mRNA expression than DKD rats injected with agomir NC. Additionally, rats treated with miR-630 agomir showed significant reductions in urinary albumin, blood glucose, TLR4, and proinflammatory markers (TNF-α, IL-1β, and IL-6) expression levels (P < 0.05). Moreover, these rats exhibited fewer kidney lesions and reduced infiltration of inflammatory cells.

Research conclusions

The miR-630 may inhibit the inflammatory reaction in DKD by targeting TLR4, and has a protective effect on DKD.

Research perspectives

The follow-up study needs to further confirm the expression difference of clinical human blood, urine or kidney tissue in diabetic nephropathy patients and its relationship with DKD staging, and further clarify the regulatory mechanism of its upstream signal pathway.